This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-25. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
(SEM-EDS): scanning electron microscopy–energy dispersive spectroscopy is used for directly studying the surfaces of solid objects, that utilizes a beam of focused electrons of relatively low energy as an electron probe that is scanned in a regular manner over the specimen. The electron source and electromagnetic lenses that generate and focus the beam are similar to those described for the transmission electron microscope (TEM). The action of the electron beam stimulates the emission of high-energy backscattered electrons and low-energy secondary electrons from the surface of the specimen. data from this process can be used to create 3D renderings of materials. (XRD): X-ray diffraction is a phenomenon in which the atoms of a crystal, by virtue of their uniform spacing, cause an interference pattern of the waves present in an incident beam of X rays. The atomic planes of the crystal act on the X rays in exactly the same manner as does a uniformly ruled grating on a beam of light. X-ray signals can be used to map estimate the concentration of elements in the sample. Microscopic Examination offers the ability to see the damage that is invisible to the naked eye, as well as aid in identifying specific materials. The identification of fibers “may not only adduce the origin of an artifact, for example, but can also serve as a predictor of behavior and so is essential in allowing an informed decision on conservation protocol.
Neanderthals ( nee-AN-də(r)-TAHL, nay-, -THAHL; Homo neanderthalensis or sometimes Homo sapiens neanderthalensis) are an extinct group of archaic humans who inhabited Europe and Western and Central Asia during the Middle to Late Pleistocene. Neanderthal extinction occurred roughly 40,000 years ago with the immigration of modern humans (Cro-Magnons), but Neanderthals in Gibraltar may have persisted for thousands of years longer. The first recognised Neanderthal fossil, Neanderthal 1, was discovered in 1856 in the Neander Valley, Germany. At first, Neanderthal 1 was considered to be one of the lower races in accord with historical race concepts. As more fossils were discovered through the early 20th century, Neanderthals were characterised as a unique species of underdeveloped human, in particular by Marcellin Boule. By the mid-twentieth century, it was believed that human evolution progressed from an ape-like ancestor through a "Neanderthal phase" to modern humans. This gave way to the "Out of Africa" theory in the 1970s. Sequencing of the Neanderthal genome in 2010 revealed that Neanderthals interbred with modern humans. Neanderthal anatomy is characterised by a long and low skull, a heavy and rounded brow ridge (supraorbital torus), an occipital bun (bony projection) at the back of the skull, strong teeth and jaws, a wide chest, and short limbs. These traits gradually became more frequent through the Middle Pleistocene of Europe, possibly due to natural selection in a cold climate, as well as genetic drift when populations collapsed during glacial periods.
Asia: United Arab Emirates (17), Saudi Arabia (13), Kuwait (7), South Korea (9), Hong Kong (8), China (5), Bahrain (4), Malaysia (3), Macau (3), Qatar (3), Singapore (2). Europe: United Kingdom (178), Spain (44), France (41), Germany (35), Italy (10), Netherlands (4), Ireland (4), Switzerland (4), Sweden (3), Austria (2), Belgium (2), Denmark (2), Luxembourg (1), Czech Republic (1). North America: United States (1,517), Canada (72). Oceania: Australia (5).
Sources: en.wikipedia.org
Technetium-99m's short half-life of 6 hours makes storage impossible and would make transport expensive (not impossible; fluorine-18 with its shorter life is transported). Instead, its parent nuclide 99Mo is supplied to hospitals after its extraction from the neutron-irradiated uranium targets and its purification in dedicated processing facilities. It is shipped by specialised radiopharmaceutical companies in the form of technetium-99m generators worldwide or directly distributed to the local market. The generators, colloquially known as moly cows, are devices designed to provide radiation shielding for transport and to minimize the extraction work done at the medical facility. A typical dose rate at 1 metre from the 99mTc generator is 20-50 μSv/h during transport. These generators' output declines with time and they must be replaced weekly, since the half-life of 99Mo is still only 66 hours. Molybdenum-99 spontaneously decays to excited states of 99Tc through beta decay. Over 87% of the decays lead to the desired 99mTc. A β− electron and a νe electron antineutrino are emitted in the process (99Mo → 99mTc + β− + νe). The β− electrons are easily shielded for transport, and 99mTc generators are only minor radiation hazards, mostly due to secondary X-rays produced by the electrons (also known as bremsstrahlung). At the hospital, the 99mTc that forms through 99Mo decay is chemically extracted from the technetium-99m generator.
=== Basal insulin === In type 1 diabetes, endogenous insulin production is extremely low or absent, and as such the body requires exogenous insulin. Some people with type 2 diabetes, particularly those with very high hemoglobin A1c values, may also require a baseline rate of exogenous insulin, as their body is desensitized to the level of insulin being produced by their body. Basal insulin regulates the body's blood glucose between mealtimes, as well as overnight. This basal rate of insulin action is generally achieved via the use of an intermediate-acting insulin (such as NPH) or a long-acting insulin analog. In type 1 diabetics, it may also be achieved via continuous infusion of rapid-acting insulin using an insulin pump. Approximately half of a person's daily insulin requirement is administered as a basal insulin, usually administered once per day at night.
=== Reports by the Western media === On 9 August 2008, the Associated Press reported that one Russian conscript said he was suddenly deployed to South Ossetia instead of expected exercises in North Ossetia. On 18 August 2008, Le Figaro published the report by journalist who was told by a young Russian soldier at some checkpoint in Georgia that he came from Shali, Chechen Republic and that they left on 5 August 2008. On 27 August 2008, the Financial Times quoted an unnamed Russian colonel as saying: "We were called to react to alarm on the night of 7th. [...] There was such an escalation of events that I cannot remember exactly when we entered the tunnel." On 29 August 2008, journalist Robert Parsons wrote in The Guardian that Russian servicemen deployed in Georgia had told him that they had been preparing for the war for weeks. In September 2008, The New York Times quoted anonymous American official as having stated that the western intelligence had information that two battalions of the 135th Regiment could have entered South Ossetia on the night of August 7. In May 2009, the United States Department of State official Matthew Bryza told Echo of Moscow that the United States knew that the Russian tank deployments to South Ossetia began in 2005 and these weaponry were used in August 2008 invasion. He confirmed that Russian tanks were entering South Ossetia before 7 August 2008, but he could not say the exact number of incoming Russian tanks on 7 August.
The prognosis is worse in those with larger burns, those who are older, and females. The presence of a smoke inhalation injury, other significant injuries such as long bone fractures, and serious co-morbidities (e.g. heart disease, diabetes, psychiatric illness, and suicidal intent) also influence prognosis. On average, of those admitted to burn centers in the United States, 4% die, with the outcome for individuals dependent on the extent of the burn injury. For example, admittees with burn areas less than 10% TBSA had a mortality rate of less than 1%, while admittees with over 90% TBSA had a mortality rate of 85%. In Afghanistan, people with more than 60% TBSA burns rarely survive. The Baux score has historically been used to determine prognosis of major burns. However, with improved care, it is no longer very accurate. The score is determined by adding the size of the burn (% TBSA) to the age of the person and taking that to be more or less equal to the risk of death. Burns in 2013 resulted in 1.2 million years lived with disability and 12.3 million disability adjusted life years.
Sources: en.wikipedia.org
Collagen alpha-1(XV) chain is a protein that in humans is encoded by the COL15A1 gene. This gene encodes the alpha chain of type XV collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Type XV collagen has a wide tissue distribution but the strongest expression is localized to basement membrane zones so it may function to adhere basement membranes to underlying connective tissue stroma. Mouse studies have shown that collagen XV deficiency is associated with muscle and microvessel deterioration. Type XV collagen is known to be a tumor suppressor that can be used to understand tumor cells environment. Type XV collagen provides the membrane with support and cell anchorage but does not typically have a tight structural network. Changes of collagen XV can be known to lead to cancer-like behavior in tissues. The loss of collagen XV would no longer provide structural support for the membrane, which can cause tumor cells to invade the basement membrane; prompting possible metastasis. The over expression of collagen XV is known to be found in cervical cancer. For possible future medical purposes the lack of collagen XV present in tissues can be a means for indication of an invasive tumor.
As of May 2019, Jollibee operated over 1,300 stores, with 1,150 in the Philippines and 234 in foreign markets. Jollibee has locations in Southeast Asia, East Asia, the Middle East, North America, Europe, and Oceania. Outside of the Philippines, Vietnam and the United States are the biggest markets for Jollibee; with 200 outlets in the former as of 2024 and 100 outlets in North America (plus Canada) as of 2024. Countries and territories with previous presence of Jollibee outlets include Taiwan, mainland China, Indonesia, Northern Mariana Islands and Papua New Guinea.
== External links == "P2Y Receptors: P2Y1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.